Waverley Pharma Inc. (FRA:5GZ)

Germany · Delayed Price · Currency is EUR

0.0100

0.00 (0.00%)

At close: Jun 26, 2026

150.00% (1Y)

Market Cap	835.32K -70.0%
Revenue (ttm)	773.81K +43.7%
Net Income	-390.58K
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0100
Previous Close	0.0100
Day's Range	0.0100 - 0.0100
52-Week Range	0.0040 - 0.0140
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Waverley Pharma

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2014

Country Canada

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 5GZ

Financial Performance

In 2025, Waverley Pharma's revenue was 1.35 million, an increase of 183.90% compared to the previous year's 475,373. Losses were -499,214, -47.29% less than in 2024.

Financial numbers in CAD Financial Statements